Stereotactic Radiotherapy for Adrenal Gland Metastases: University of Florence Experience

• Published in: International journal of radiation oncology, biology, physics Vol. 82; no. 2; pp. 919 - 923
• Main Authors: Casamassima, Franco, M.D., Ph.D, Livi, Lorenzo, M.D, Masciullo, Stefano, M.D, Menichelli, Claudia, M.D, Masi, Laura, Ph.D, Meattini, Icro, M.D, Bonucci, Ivano, M.D, Agresti, Benedetta, M.D, Simontacchi, Gabriele, M.D, Doro, Raffaela, Ph.D
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-02-2012; Elsevier
• Subjects: Adrenal gland metastases; Adrenal Gland Neoplasms - diagnostic imaging; Adrenal Gland Neoplasms - mortality; Adrenal Gland Neoplasms - secondary; Adrenal Gland Neoplasms - surgery; ADRENAL GLANDS; Adult; Aged; Algorithms; Biological and medical sciences; Dose Fractionation; FAILURES; Female; Follow-Up Studies; Genital system. Mammary gland; Hematology, Oncology and Palliative Medicine; Humans; Male; Medical sciences; METASTASES; Middle Aged; Multidetector Computed Tomography; Oligometastases; PATIENTS; RADIATION DOSES; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; Radiosurgery; Radiosurgery - adverse effects; Radiosurgery - methods; RADIOTHERAPY; Radiotherapy, Image-Guided - methods; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Respiration; Retrospective Studies; Stereotactic body radiotherapy; SURGERY; Survival Rate; Tumor Burden; Stereotactic body radiotherapy; Adrenal gland metastases; Radiotherapy; Oligometastases; Radiosurgery; Endocrinopathy; Human; Prognosis; Adrenal glands; Malignant tumor; Metastasis; Cancerology; Treatment; Adrenal gland diseases; Cancer
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2010.11.060

Purpose To evaluate a retrospective single-institution outcome after hypofractionated stereotactic body radiotherapy (SBRT) for adrenal metastases. Methods and Materials Between February 2002 and December 2009, we treated 48 patients with SBRT for adrenal metastases. The median age of the patient population was 62.7 years (range, 43–77 years). In the majority of patients, the prescription dose was 36 Gy in 3 fractions (70% isodose, 17.14 Gy per fraction at the isocenter). Eight patients were treated with single-fraction stereotactic radiosurgery and forty patients with multi-fraction stereotactic radiotherapy. Results Overall, the series of patients was followed up for a median of 16.2 months (range, 3–63 months). At the time of analysis, 20 patients were alive and 28 patients were dead. The 1- and 2-year actuarial overall survival rates were 39.7% and 14.5%, respectively. We recorded 48 distant failures and 2 local failures, with a median interval to local failure of 4.9 months. The actuarial 1-year disease control rate was 9%; the actuarial 1- and 2-year local control rate was 90%. Conclusion Our retrospective study indicated that SBRT for the treatment of adrenal metastases represents a safe and effective option with a control rate of 90% at 2 years.